CD14 and common variable immunodeficiency: We now report that IVIg treatment of CVID patients provokes the acquisition of an anti-inflammatory profile in PBMC and monocytes, and that IVIg enhances the percentage of CD14+ monocytes with a transcriptional, phenotypic, and functional profile compatible with those of myeloid-derived suppressor cells (MDSC).